Immunotherapy for colorectal cancer: A challenge to clinical trial design

Lancet Oncology

Volumn 1, Issue 3, 2000, Pages 159-168

  Midgley, Rachel ^a   Kerr, David ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; PRODRUG; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL TUMOR; CYTOTOXICITY; HUMAN; IMMUNOLOGY; METHODOLOGY; PASSIVE IMMUNIZATION; REVIEW; VACCINATION;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CLINICAL TRIALS; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; PRODRUGS; RESEARCH DESIGN; VACCINATION;

EID: 0034334393     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00034-6     Document Type: Review

References (49)

1. Smith ME, Marsh SG, Bodmer JG, et al. Loss of HLA-A, B, C allele products and lymphocyte function associated antigens in colorectal neoplasia. Proc Natl Acad Sci USA 1989; 89: 5557-61.
2. Lopez-Neust MA, Esteban F, Ferron A, et al. HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective loss of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989; 59: 221-26.
3. Bicknell DC, Kaklamanis L, Hampson R, Bodner WF, Kerran P. Selection for b2 microglobulin mutation in mis-match repair-defective colorectal carcinomas. Curr Biol 1996; 6: 1695-97.
4. Kaklamanis L, Townsend A, Dousssis-Anagnostopoulou IA. Loss of major histocompatability complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol 1994; 145: 505-09.
5. Gimmi CD, Morrison BW, Mainprice BA, et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 1996; 2: 1367-70.
6. Gastl GA, Abrams JS, Nanus DM, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993; 55: 96-101.
7. Kanai T, Watanabe M, Hayashi A, et al. Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion. Br J Cancer 2000; 82: 1717-23.
8. Harding FA, McArthur JG, Gross JA, et al. CD28-mediated signalling co-stimulates T-cells and prevents induction of anergy in T-cell clones. Nature 1992; 356: 607-09.
9. Younes M, Schwartz MR, Finnie D, Younes A. Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the oesophagus. Hum Pathol 1999; 30: 1309-13.
10. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 2000; 82: 1009-12.
11. Falk RE, MacGregor AB, Landi S, et al. Immunostimulation with intraperitoneally administered Bacille-Calmette Guerin for advanced malignant tumours of the GI tract. Surg Gynecol Obstet 1976; 12: 363-68.
12. Mavligit GM, Gutterman JU, Malahy MA, et al. Adjuvant immunotherapy and chemotherapy in colorectal cancer (Dukes'class C); prolongation of disease-free interval and survival. Cancer 1977; 40 (5suppl): 2726-30.
13. Gastro-intestinal Tumour Study Group. Adjuvant therapy of colon cancer: results of a prospectively randomised trial. N Engl J Med 1984; 310: 737-43.
14. Quasar Collaborative Group. Comparison of fluorouracil with addition of levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000; 355: 1588-96.
15. Rosenberg SA, Lope MT, Yang JC, et al. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-85.
16. Brivio F, Lissini P, Alden G, et al. Pre-operative IL-2 sub-cutaneous immunotherapy may prolong survival time in advanced colorectal patients. Oncology 1996; 53: 263-68.
17. Douillard JY, Bennouna J, Vavasseur F, et al. Phase I trial of interleukin-2 and high dose arginine butyrate in metastatic colorectal cancer. Cancer Immunol Immunother 2000; 49: 56-61.
18. Seymour MT, Stevin HL, Kerr DJ, et al. Randomised trial assessing the addition of interferona2a to fluourouracil and leucovorin in advanced colorectal cancer. J Clin Oncol 1996; 14: 2280-88.
19. Southern Italy Oncology Group. 5-fluorouracil and levofolinic acid with or without recombinant interferona2b in patients with advanced colorectal carcinoma. Cancer 1999; 85: 535-45.
20. Hausminger H, Moser R, Samonigg H, et al. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferona2c in patients with advanced colorectal cancer: final results of a randomised phase III study. Eur J Cancer 1999; 35: 380-85.
21. Fountzilas G, Zisiadis A. Pafni U, et al. Fluorouracil and leucovorin with or without interferona2a as adjuvant treatment, in patients with high risk colon cancer. Oncology 2000; 58: 227-36.
22. Riethmuller G, Holz, E, Schliomock G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven year outcome of a multi-centre randomised trial. J Clin Oncol 1998; 16: 1788-94.
23. Napier MP, Sharma SK, Springer CJ, et al. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 2000; 6: 765-72.
24. Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphocyte-activated killer cells and recombinant interleukin-2. Cancer Res 1985; 45: 3735-41.
25. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphocyte-activated killer cells and recombinant interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987; 316: 889-97.
26. Kim A, Bresler H, Martin EW, et al. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localised in vivo by radiolabelled monoclonal antibody. Cancer 1999; 86: 22-30.
27. Tsang KY, Zhu M, Nieroda CA, et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcino-embryonic antigen. Clin Cancer Res 1997; 3: 2439-49.
28. Hoover HC Jr, Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer:6.5 year median follow-up of a phase III prospectively randomised trial. J Clin Oncol 1993; 11: 390-99.
29. Harris JE, Rajan L, Hoover HC, et al. Adjuvant ASI for stage II and III colon cancer with autologous tumour cell vaccine: Eastern Cooperative Oncology Group Study, E5283. J Clin Oncol 2000; 18: 148-57.
30. Vermorken JB, Claessen AME, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353: 345-50.
31. Chong H, Todryk S, Hutchinson G, et al. Tumour cell expression of B7 co-stimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local anti-tumour response and may generate systemic protective immunity. Gene Ther 1998; 5: 223-32.
32. Sobol RE, Shawler DC, Carson C. Interleukin-2 gene therapy of colorectal carcinoma with autologous irradiated tumour cells and genetically-engineered fibroblasts: a phase I study. Clin Cancer Res 1999; 5: 2359-65.
33. Austin EB, Robins RA, Durrant LG, Price MR, Baldwin RW. Human monoclonal anti-idiotypic antibody 791T/36. Immunology 1989; 67: 525-30.
34. Denton GWL, Durrant LG, Hardcastle JD, et al. Clinical outcome of colorectal cancer patients treated with human monocloncal anti-idiotyic antibody. Int J Cancer 1994; 57: 10-14.
35. Durrant LG, Maxwell-Armstrong C, Buckley D, et al. A neo-adjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin Cancer Res 2000; 6: 422-30.
36. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A phase I trial of synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinomas. J Surg Res 1996; 63: 298-304.
37. Reddish MA, MacClean GP, Poppema S, et al. Pre-immunotherapy serum CA27.29 (MUC1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996; 42: 303-09.
38. Khleif SN, Abrams SI, Hamilton JM, et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumours. J Immunother 1999; 22: 155-65.
39. Nukaya I, Yasumoto M, Iwasaki T, et al. Identification of HLA-A24 epitope peptides of carcino-embryonic antigen which induce tumour-reactive cytotoxic T lymphocytes. Int J Cancer 1999; 80: 92-97.
40. Kawashimi I, Tsai V, Southwood S, et al. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcino-embryonic antigen and Her2/neu by priming in vitro immunisation with peptide-pulsed dendritic cells. Cancer Res 1999; 59: 431-35.
41. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T-cells specific for human carcino-embryonic antigen epitopes from patients immunised with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1999; 87: 982-90.
42. Marshal JL, Hawkins MJ, Tsang KY, et al, Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcino-embryonic antigen. J Clin Oncol 1999; 17: 332-37.
43. Arlen P, Marshall J, Hamilton M, et al. Use of a rapid elispot system for the detection of immune responses in cancer patients receiving CEA vaccines. Proc Am Soc Clin Oncol 2000; 19: 463a (abstr 1817).
44. Von Mehrn M, Davey M, McLaughlin S, et al. Phase I study of vaccine therapy with ALVAC-CEA/B7.1 and GMCSF (G) in patients with advanced CEA-expressing malignancies. Proc Am Soc Clin Oncol 2000; 19: 482a (abstr 1883).
45. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of co-stimulatory molecules synergises to amplify T-cell activation. Cancer Res 1999; 59: 5800-07.
46. Alters SE, Gadea JR, Sorich M, et al. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with a restricted TCR repertoire. J Immunother 1998; 21: 17-26.
47. Morse MA, Deng Y, Coleman D, et al. A phase I study of active immunothrapy with carcinoembryonic antigen peptide (CAP-1)-pulsed autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcino-embryonic antigen. Clin Cancer Res 1999; 5: 1331-8.
48. Shimizu K, Fields RC, Redman BG, Giedlin M, Mule JJ. Potentiation of immunologic responsiveness to dendritic-cell-based tumour vaccines by recombinant interleukin-2. Cancer J Sci Am 2000; 6 (suppl 1): 567-75.
49. Mose MA, Mosca PJ, Hobeika A, et al. Immunotherapy with Flt-3 ligand-mobilised dendritic cells (DC) loaded with carcino-embryonic antigen (CEA) peptide (CAP-1) in patients with metastatic malignancies expressing CEA. Proc Am Soc Clin Oncol 2000; 19: 496a (abstr 1840).